$PG

PG, SFM, EDU, STLD, BAX trending with analysts - TipRanks.com

TipRanks highlights analyst activity on PG, SFM, EDU, STLD and BAX. HSBC cut PG to Hold, trimming its $149 target, citing flat organic sales and weaker momentum. J.P. Morgan upgraded SFM to Buy, $103 target. Macquarie raised EDU to Hold, $56.50. Nick Cash initiated STLD Buy, $300 target. Citi upgraded BAX to Hold, $28 target, citing Q2 sales of $2.96B.

Original reporting
Published Aug 1, 2026, 9:17 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 1, 2026, 11:01 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefFinancial news
Primary signal
$PG
Bearish
medium confidence
Mentioned
$PG · $SFM · $EDU · $STLD · $BAX
Relevance
4/10
alphai data visualization · based on tipranks.com
Decision brief

The 30-second read

$PGBearishMed
01

Why it matters

The actionable element is the set of fresh analyst actions: PG downgraded to Hold, SFM upgraded to Buy, EDU upgraded to Hold, STLD initiated at Buy, and BAX upgraded to Hold with raised guidance cited.

02

Market read

Traders can use the analyst actions as near-term catalysts for positioning, but the article is not a primary disclosure like an earnings release or regulatory decision.

03

What to watch

For BAX, the tariff refund timing could create a misleading margin comparison. For EDU, overseas restructuring and cost issues are flagged as the key risk despite the revenue beat.

Relevance 4/10Novelty 5/10Timing: pre-market today, analyst rating and price-target changes driving near-term positioning

Background

TipRanks summarizes analyst rating changes across five stocks, with each note tied to a specific thesis and (in most cases) a revised price target.

Company-level read

Ticker impact

$PGBearishMedium confidence
Context

HSBC cut PG to Hold and trimmed its target, citing flat organic sales, weaker momentum, and FY27 guidance framed as a transition year.

Expected impact

Near-term downside bias versus peers as traders price in slower growth proof and reduced upside from current multiples.

Evidence & confidence

The article provides a clear rating change (Hold) plus specific thesis points (flat organic sales, operating income miss, transition-year guidance), which typically pressures sentiment even without a new earnings print in the text.

$SFMBullishMedium confidence
Context

J.P. Morgan upgraded SFM to Buy and raised its price target, pointing to 2Q26 beats and guidance implying positive same-store sales growth from 3Q26.

Expected impact

Near-term upside bias as the market reacts to the upgrade and higher target tied to same-store growth expectations.

Evidence & confidence

The article includes both the rating change and a forward-looking catalyst (same-store sales growth from 3Q26) supported by 2Q26 beats and guidance.

$EDUNeutralMedium confidence
Context

Macquarie upgraded EDU to Hold and lifted its target after 4Q revenue grew 23% YoY and management guided for double-digit FY27 growth.

Expected impact

Limited upside bias, with volatility risk if overseas margin/cost issues worsen versus the improved growth narrative.

Evidence & confidence

The article provides a concrete rating/target change and specific operating/margin details, but keeps the stance at Hold due to overseas profitability uncertainty.

$STLDBullishLow confidence
Context

Nick Cash initiated coverage on STLD with a Buy and a $300 12-month target, emphasizing diversified steel exposure and margin-accretive aluminum expansion.

Expected impact

Moderate upside bias as fresh coverage can attract incremental flows, especially after a pullback mentioned in the text.

Evidence & confidence

This is an initiation rather than a new fundamental event; the article’s key drivers are thesis-based (diversification, aluminum expansion) with limited hard datapoints beyond the target and forward FCF yield.

$BAXNeutralMedium confidence
Context

Citi upgraded BAX to Hold from Sell and raised its target to $28 after 2Q sales of $2.96B grew 5% organically and guidance was raised.

Expected impact

Stabilization bias with potential upside if margin trajectory holds after the tariff refund benefit fades.

Evidence & confidence

The article includes a clear upgrade plus specific quarter metrics (organic growth, segment growth) and a concrete margin caveat (tariff refund), which matters for near-term positioning.

Market effects

Cross-sector read-through: consumer staples (PG) faces growth skepticism, retail grocery (SFM) gets a positive demand narrative, education (EDU) hinges on overseas margin execution, steel (STLD) benefits from diversification/aluminum framing, and medtech (BAX) trades on turnaround credibility.

Primarily US-listed single-name sentiment shifts; no explicit regional macro catalyst described.

Limited. The only global linkage is tariff-related margin noise referenced for BAX, without broader policy detail.

Counterpoint

Analyst upgrades/downgrades may be more about valuation and narrative than new company fundamentals; tariff and restructuring uncertainties could dominate realized results.

Key entities

  • Procter & Gamble

    Analyst HSBC cut PG to Hold and trimmed its target, citing flat organic sales and weaker momentum.

  • Sprouts Farmers Market

    J.P. Morgan upgraded SFM to Buy and raised its target on 2Q beats and guidance for same-store growth.

  • New Oriental Education & Technology

    Macquarie upgraded EDU to Hold and raised its target after a 4Q revenue beat and shareholder return appeal.

  • Steel Dynamics

    Coverage initiated on STLD with a Buy and $300 target, emphasizing diversification and aluminum expansion.

  • Baxter International

    Citi upgraded BAX to Hold from Sell, citing 2Q organic sales growth and raised 2026 guidance, while flagging margin sensitivity.

Related articles

$PGMedAI 8/10

P&G’s Wellness Focus Grows Following US$3.8bn Thorne Deal

Procter & Gamble (P&G) said it will expand its health care and wellness portfolio after agreeing to buy Thorne for US$3.8bn. P&G plans to broaden a portfolio that includes Vicks, Crest, Oral-B and supplements such as Align Probiotic. Thorne’s revenue rose from about US$229m (2022) to over US$500m (2025), with US$650m targeted in 2026; deal closes later in 2026 pending approvals.

$PGMed

Procter & Gamble acquires dietary supplement manufacturer

Procter & Gamble will acquire dietary supplement maker Thorne for $3.8 billion, according to the companies. P&G, owner of brands including Ariel, Gillette, Oral-B, and Pampers, said the deal targets its health and wellness business. Thorne, founded in 1984, went public in 2021 and was taken private in 2023 by L Catterton.

$PGMedAI 9/10

P&G Intensifies Wellness Push With Latest Acquisition

Procter & Gamble (P&G) will acquire supplements maker Thorne for $3.8 billion in cash from L Catterton, according to the companies. P&G said the deal supports its health and wellness strategy. Thorne had forecast $290 million sales for 2023 and CNBC reported $650 million for 2024. P&G also forecast slower annual sales growth.

$PGMed

Wellness Briefing: A new class of oral care disruptors hopes to shake up the space with novel offerings, plus news

The U.S. oral-care market is $12.36B (2026 est.) and projected to reach $14.56B by 2031, according to Mordor Intelligence. New DTC brands Evenmouth, Bastét and Köppen are launching microbiome or hydroxyapatite-based products and multi-step systems. Incumbents Colgate-Palmolive, P&G, Unilever and Kenvue face slower oral-care sales; P&G CFO said it is deciding how to innovate. Separately, P&G will buy Thorne for $3.8B.

PG, SFM, EDU, STLD, BAX trending with analysts - TipRanks.com — alphai